Advertisement
Advertisement
NVAX
Novavax Inc
7.74
USDSponsored
+0.04
+0.52%
Aug 06, 16:00 UTC -4
Closed
Pre-Market
7.83
+0.09
+1.23%
NVAX Earnings Reports
Positive Surprise Ratio
NVAX beat 20 of 43 last estimates.
47%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$101.60M
/-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+79.20%
/-71.88%
Implied change from Q3 25 (Revenue/ EPS)
+44.23%
/-92.80%
Novavax Inc earnings per share and revenue
On Aug 06, 2026, NVAX reported earnings of -0.32 USD per share (EPS) for Q2 26, beating the estimate of -0.41 USD, resulting in a 22.65% surprise. Revenue reached 56.70 million, compared to an expected 52.12 million, with a 8.79% difference. The market reacted with a +0.52% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 101.60 million USD, implying an decrease of -71.88% EPS, and increase of 79.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Corvus Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-17.36%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Immunovant, Inc. Common Stock
Report Date
Aug 06, 2026 For Q1 27
Estimate
-$0.62
Actual
-$0.75
Surprise
-19.48%
Xenon Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.16
Actual
-$1.11
Surprise
+4.36%
FAQ
What were Novavax Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Novavax Inc reported EPS of -$0.32, beating estimates by 22.65%, and revenue of $56.70M, 8.79% above expectations.
How did the market react to Novavax Inc's Q2 2026 earnings?
The stock price moved up 0.52%, changed from $7.70 before the earnings release to $7.74 the day after.
When is Novavax Inc expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Novavax Inc's next earnings report?
Based on 7
analysts, Novavax Inc is expected to report EPS of -$0.09 and revenue of $101.60M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement